Fatty Acid Oxidation Disorders (FAODs) Market Growth To $14.69 Billion Creates New Opportunities Across The Industry

Fatty Acid Oxidation Disorders (FAODs) Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Fatty Acid Oxidation Disorders (FAODs) Market CAGR Outlook And Future Development

The market for fatty acid oxidation disorders (FAODs) has experienced robust growth in recent years. It is projected to expand from $10.23 billion in 2025 to $11.01 billion by 2026, achieving a compound annual growth rate (CAGR) of 7.6%. This historical expansion can be attributed to factors such as the implementation of neonatal screening initiatives, an increased diagnosis of inherited metabolic disorders, improved clinical awareness, the expansion of hospital-based metabolic clinics, and the availability of supportive drug therapies.

The market size for fatty acid oxidation disorders (faods) is set to demonstrate robust growth over the next few years. It is projected to expand to $14.69 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period is primarily driven by progress in enzyme replacement therapies, the expansion of genetic research, an increase in personalized nutrition plans, better reimbursement policies for rare diseases, and more government support for early screening. Prominent trends anticipated in the forecast period include the increasing adoption of newborn screening programs, a greater focus on the early diagnosis of metabolic disorders, the growing utilization of nutritional and dietary management, broadened awareness of rare disease treatments, and improved access to therapies for metabolic disorders.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=85286714&type=smp&name=Fatty%20Acid%20Oxidation%20Disorders%20%28FAODs%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Fatty Acid Oxidation Disorders (FAODs) Market Industry Drivers: What’s Behind The Revenue Growth?

The growing need for gene therapy is anticipated to boost the expansion of the fatty acid oxidation disorders (FAODs) market moving forward. Gene therapy is defined as a medical approach involving the alteration or replacement of faulty genes to either treat existing diseases or prevent their occurrence. This rising demand for gene therapy is attributed to its capability to address genetic conditions, cancer, and rare diseases by targeting their fundamental genetic causes, thereby attracting significant investments and fostering advancements in biotechnology. For fatty acid oxidation disorders, gene therapy aims to rectify metabolic shortcomings by delivering functional genes, restoring enzymatic activity, improving energy production, and averting disease complications. Illustrating this, the American Society of Gene & Cell Therapy (ASGCT), a US-based nonprofit professional medical and scientific organization, reported in 2024 that the global pipeline of gene, cell, and RNA therapies increased from 3,483 in Q4 2022 to 3,951 in Q4 2023, ultimately reaching 4,238 in Q4 2024. Therefore, the heightened demand for gene therapy is a significant driver for the growth of the fatty acid oxidation disorders (FAODs) market.

Fatty Acid Oxidation Disorders (FAODs) Market Breakdown By Product Type And Application

The fatty acid oxidation disorders (faods) market covered in this report is segmented –

1) By Type: Long Chain, Short Chain

2) By Drug Type: Levocarnitine, Dextrose, Riboflavin, Other Drug Types

3) By Route of Administration: Oral, Intravenous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores

5) By End User: Hospitals, Clinics, Pharmaceutical Companies

Subsegments:

1) By Long Chain: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD), Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD), Trifunctional Protein Deficiency (TFP), Carnitine Palmitoyltransferase II Deficiency (CPT II)

2) By Short Chain: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD), Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD), Carnitine Uptake Defect (CUD)

Fatty Acid Oxidation Disorders (FAODs) Market Growth Trends Reshaping The Competitive Landscape

Leading companies in the fatty acid oxidation disorders (FAODs) market are concentrating on developing innovative solutions, such as peroxisome proliferator-activated receptor delta (PPARd) agonists, to improve metabolic control and enhance treatment outcomes for patients with FAODs. A PPARd agonist is a compound that stimulates the PPARd receptor, which plays a role in regulating lipid metabolism, inflammation, and energy balance, potentially offering therapeutic benefits for metabolic disorders and cardiovascular diseases. For instance, in January 2023, Reneo Pharmaceuticals Inc., a U.S.-based clinical-stage pharmaceutical company, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its investigational drug, Mavodelpar (REN001). This drug targets long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a genotype associated with long-chain fatty acid oxidation disorder (LC-FAOD). By activating PPARd, mavodelpar intends to enhance mitochondrial function, improve energy metabolism, and mitigate symptoms linked to LC-FAOD.

Fatty Acid Oxidation Disorders (FAODs) Market Company Landscape And Competitive Strategy

Major companies operating in the fatty acid oxidation disorders (faods) market are Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc, Sanofi SA, Novo Nordisk A S, Pfizer Inc, Merck & Co Inc, AstraZeneca PLC, Amgen Inc, AbbVie Inc, BioMarin Pharmaceutical Inc, PTC Therapeutics Inc, Horizon Therapeutics PLC, Recordati Rare Diseases SpA, Orphazyme A S, Mitsubishi Tanabe Pharma Corporation, Alexion Pharmaceuticals Inc (AstraZeneca Rare Disease), REGENXBIO Inc, Avrobio Inc, Homology Medicines Inc, Abeona Therapeutics Inc

View The Full Fatty Acid Oxidation Disorders (FAODs) Market Report:

https://thebusinessresearchcompany.com/report/fatty-acid-oxidation-disorders-faods-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Fatty Acid Oxidation Disorders (FAODs) Market Largest Region: Which Geography Holds The Biggest Share?

Asia-Pacific was the largest region in the fatty acid oxidation disorders (FAODs) market in 2025. The regions covered in the fatty acid oxidation disorders (faods) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model